Obefazimod is an oral small-molecule drug candidate in clinical development for the treatment of moderately to severely active ulcerative colitis (UC) and has demonstrated anti-inflammatory activity in preclinical studies and in both Phase 2a and Phase 2b clinical trials.

Due to the pathophysiological and clinical similarities of Crohn’s disease (CD) and UC, Abivax believes obefazimod has the potential to show beneficial effects in patients suffering from CD and plans to initiate a Phase 2a clinical trial in patients with CD to potentially demonstrate outcomes consistent with those observed in its Phase 2 clinical trials for moderately to severely active UC.

Based on the encouraging safety profile and tolerability results observed with obefazimod in UC, Abivax is planning to initiate a Phase 2a clinical trial for the treatment of CD.